Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 362-372

  Wexler, L H ^a   Andrich, M P ^a   Venzon, D ^a   Berg, S L ^a   Weaver McClure, L ^a   Chen, C C ^a   Dilsizian, V ^a   Avila, N ^a   Jarosinski, P ^a   Balis, F M ^a   Poplack, D G ^a   Horowitz, M E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; RAZOXANE;

ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA;

EID: 9044233260     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.362     Document Type: Article

References (49)

1. Muggia FM, Green MD: New anthracycline anti tumor antibiotics. Crit Rev Oncol Hematol 11:43-64, 1991
2. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
3. Dresdale AM, Bonow RO, Wesley R, et al: Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 52:51-60, 1983
4. Nesbit ME, Gehan EA, Burgert EO, et al: Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the first intergroup study. J Clin Oncol 8:1664-1674, 1990
5. Burgert EO, Nesbit ME, Garnsey LA, et al: Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 8:1514-1524, 1990
6. Hitchock-Bryan S, Gelber R, Cassady JR, et al: The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 14:211-215, 1986
7. Smith MA, Ungerleider RS, Horowitz ME, et al: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83:1460-1470, 1981
8. Bacci G, Picci P, Ferrari S, et al: Influence of Adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: Results of two sequential studies. J Chemother 5:237-246, 1993
9. Gilladoga AC, Manuel C, Tan CC, et al: Cardiotoxicity of adriamycin (NSC-123127) in children. Cancer Chemother Rep 6:209-214, 1975
10. Pratt CB, Ransom JL, Evans WE: Age-related Adriamycin cardiotoxicity in children. Cancer Treat Rep 62:1381-1385, 1978
11. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
12. Steinherz LJ, Steinherz PG, Tan CTC, et al: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677, 1991
13. Riggs CE: Antitumor antibiotics and related compounds, in Perry MC (ed): The Chemotherapy Source Book. Baltimore, MD, Williams & Wilkins, 1992, pp 318-358
14. Zhang J, Herman EH, Ferrans VJ: Dendritic cells in the hearts of spontaneously hypertensive rates treated with doxorubicin with or without ICRF-187. Am J Pathol 142:1916-1926, 1993
15. Herman EH, Ferrans VJ: Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline induced chronic cardiomyopathy. Cancer Treat Rev 17:155-160, 1990
16. Dardir M, Herman EH, Ferrans VJ: Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 23:267-275, 1989
17. Doroshow JH: Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res 43:4543-4551, 1983
18. Myers C, Gianni L, Zweier J, et al: Role of iron in Adriamycin biochemistry. Fed Proc 45:2792-2797, 1986
19. Sobol MM, Amiet RG, Green MD: In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex. Mol Pharmacol 41:8-16, 1991
20. Hasinoff BB: The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of Adriamycin. Agents Act 26:378-385, 1989
21. Vats T, Kamen B, Krischer JP: Phase II trial of ICRF-187 in children with solid tumors and acute leukemia. Invest New Drugs 9:333-337, 1991
22. Herman E, Ardalan B, Bier C, et al: Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treat Rep 63:89-92, 1979
23. Herman EH, Ferrans VJ, Jordan W, et al: Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chemother Pathol Pharmacol 31:85-97, 1981
24. Herman EH, Ferrans VJ: Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). Cancer Res 41:3436-3440, 1981
25. Green MD, Alderton P, Gross J, et al: Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529). Pharmacol Ther 48:61-69, 1990
26. Wadler S, Green MD, Muggia FM: Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) against the murine sarcoma S180 cell line. Cancer Res 46:1176-1181, 1986
27. Wadler S, Green MD, Basch R, et al: Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2,-bis(3-5-dioxopiperazinyl-1-yl)propane (ICRF-187), on murine sarcoma S180 in vitro. Biochem Pharmacol 36:1495-1501, 1987
28. Speyer JL, Green MD, Kramer E, et al: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745-752, 1988
29. Horowitz M, Balis F, Pastakia B, et al: Integration of ifosfamide and VP-16 (IE) into the front-line therapy of pediatric sarcomas (PS). Proc Am Soc Clin Oncol 7:260, 1988 (abstr)
30. Druck MN, Guilenchyn KY, Evans WK, et al: Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 53:1667-1674, 1984
31. Bonow RO, Kent KM, Rosing DR, et al: Improved left ventricular diastolic filling in patients with coronary artery disease after percutaneous transluminal coronary angioplasty. Circulation 66: 1159-1167, 1982
32. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
33. Kisner DL: Reporting treatment toxicities, in Buyse ME, Staquet MJ, Sylvester RJ (eds): Cancer Clinical Trials: Methods and Practice. Oxford, United Kingdom, Oxford University Press, 1984, pp 178-190
34. Earhart R, Tutsch K, Koeller J, et al: Pharmacokinetics of (+)-1,2-di(3,5 dioxopiperazin-1-yl) propane intravenous infusions in adult cancer patients. Cancer Res 42:5255-5261, 1982
35. Knott G: MLAB - A mathematical modelling tool. Comput ProgrBiomed 10:271-280, 1979
36. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175, 1978
37. Oberlin O, Habrand JL, Zucker JM, et al: No benefit of ifosfamide in Ewing's sarcoma: A nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 10:1407-1412, 1992
38. Hochster J, Liebes L, Wadler S, et al: Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84:1725-1730, 1992
39. Horowitz ME, Kinsella TJ, Wexler LH, et al: Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 11:1911-1918, 1993
40. Steinherz LJ, Graham T, Hurwitz R, et al: Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 89:942-949, 1992
41. Jakacki RI, Larsen RL, Barber G, et al: Comparison of cardiac function tests after anthracycline therapy in children. Implications for screening. Cancer 72:2739-2745, 1993
42. Lipshultz SE, Sanders SP, Goorin AM, et al: Monitoring for anthracycline cardiotoxicity. Pediatrics 93:433-437, 1994
43. Alexander J, Dainiak N, Berger HJ, et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300:278-283, 1979
44. Palmeri ST, Bonow RO, Myers CE, et al: Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography, Am J Cardiol 58:607-613, 1986
45. Schwartz RG, McKenzie WB, Alexander J, et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 82:1109-1118, 1987
46. Hortobagyi GN, Frye D, Buzdar AU, et al: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63:37-45, 1989
47. Judson IR: Anthrapyrazoles: true successors to the anthracyclines? Anticancer Drugs 2:223-231, 1991
48. Green MD, Alderton P, Sobol MM, et al: ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: Clinical and preclinical studies, in Muggia FM (ed): New Drugs, Concepts and Results in Cancer Chemotherapy. Boston, MA, Kluwer Academic, 1992, pp 101-117
49. Lippens RJJ, van Lier HJJ, Zwagemakers JFC: Tolerance of 24-hour infusions of low- and high-dose bolus injections of Adriamycin in children. Pediatric Hematol Oncol 4:189-197, 1987